Where Will Travere Therapeutics Inc (TVTX) Stock Go Next After It Has Fallen 2.45% in a Week?

The market has been down on Travere Therapeutics Inc (TVTX) stock recently. TVTX gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Travere Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on TVTX!

See Full TVTX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With TVTX Stock Today?

Travere Therapeutics Inc (TVTX) stock is unchanged 0% while the S&P 500 is higher by 0.4% as of 2:13 PM on Wednesday, Mar 27. TVTX is flat $0.00 from the previous closing price of $7.57 on volume of 500,676 shares. Over the past year the S&P 500 is higher by 31.35% while TVTX is lower by -65.02%. TVTX lost -$5.07 per share in the over the last 12 months. To screen for more stocks like Travere Therapeutics Inc click here.

More About Travere Therapeutics Inc

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease. Click Here to get the full Stock Report for Travere Therapeutics Inc stock.